Loading…
Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. The company offers robotic magnetic navigation (RMN) systems, such as Genesis RMN, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites; and GenesisX RMN System, which is designed to enhance the accessibility of Robotic Magnetic Navigation by reducing the lengthy construction cycle necessary to install prior generation RMN systems. It also offers Odyssey, a Synchrony and SynX Solution offer integrated, real-time information solution to manage, control, record and share procedures across networks; and x-ray systems. In addition, the company offers disposables and other accessories, including MAGiC catheter, a robotically navigated magnetic ablation catheter designed to perform minimally invasive cardiac ablation procedures; MAGiC Sweep, a mapping catheter; QuikCAS, an automated catheter advancement single-use disposable device; iCONNECT; and V-CAS devices. Further, it provides interventional devices under the Map-iT, MAGiC, and EMAGIN brands, and other related devices. It markets its products through direct sales force, distributors, and sales agents. Stereotaxis, Inc. was incorporated in 1990 and is based in Saint Louis, Missouri.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $32M | $-21M | $-22M | $-14M | -160.5% | 20.3% | -10.0% |
| 2024 | $27M | $-24M | $-24M | $-9M | -395.5% | 0.5% | 16.1% |
| 2023 | $27M | $-21M | $-21M | $-10M | -126.7% | -4.9% | 13.2% |
| 2022 | $28M | $-18M | $-18M | $-11M | -69.4% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 28.15 | 26.77 | 26.92 | 32.38 |
| Operating Revenue | - | 28.15 | 26.77 | 26.92 | 32.38 |
| Cost Of Revenue | - | 9.68 | 11.91 | 12.32 | 15.31 |
| Gross Profit | - | 18.47 | 14.86 | 14.59 | 17.07 |
| Operating Expense | - | 37.25 | 36.70 | 39.33 | 39.18 |
| Research And Development | - | 10.56 | 10.27 | 9.76 | 9.38 |
| Selling General And Administration | - | 26.69 | 26.43 | 29.57 | 30.29 |
| Total Expenses | - | 46.92 | 48.61 | 51.66 | 54.49 |
| Operating Income | - | -18.78 | -21.84 | -24.74 | -22.11 |
| Total Operating Income As Reported | - | -18.78 | -21.84 | -24.74 | -22.11 |
| EBITDA | - | -18.35 | -21.24 | -23.77 | -20.56 |
| Normalized EBITDA | - | -18.35 | -21.24 | -23.77 | -20.56 |
| EBIT | - | -18.78 | -21.84 | -24.74 | -22.11 |
| Interest Income | - | 0.48 | 1.10 | 0.69 | 0.47 |
| Net Interest Income | - | 0.48 | 1.10 | 0.69 | 0.47 |
| Other Non Operating Income Expenses | - | - | 0.03 | - | 0 |
| Other Income Expense | 2.18 | - | 0.03 | - | 0 |
| Interest Income Non Operating | - | 0.48 | 1.10 | 0.69 | 0.47 |
| Net Non Operating Interest Income Expense | - | 0.48 | 1.10 | 0.69 | 0.47 |
| Pretax Income | - | -18.29 | -20.71 | -24.04 | -21.64 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -18.29 | -20.71 | -24.04 | -21.64 |
| Net Income From Continuing And Discontinued Operation | - | -18.29 | -20.71 | -24.04 | -21.64 |
| Net Income From Continuing Operation Net Minority Interest | - | -18.29 | -20.71 | -24.04 | -21.64 |
| Net Income | - | -18.29 | -20.71 | -24.04 | -21.64 |
| Net Income Common Stockholders | - | -19.64 | -22.06 | -25.35 | -22.91 |
| Net Income Including Noncontrolling Interests | - | -18.29 | -20.71 | -24.04 | -21.64 |
| Normalized Income | - | -18.29 | -20.71 | -24.04 | -21.64 |
| Diluted NI Availto Com Stockholders | - | -19.64 | -22.06 | -25.35 | -22.91 |
| Basic Average Shares | - | 76.06 | 80.70 | 85.18 | 90.96 |
| Diluted Average Shares | - | 76.06 | 80.70 | 85.18 | 90.96 |
| Reconciled Depreciation | - | 0.43 | 0.60 | 0.97 | 1.56 |
| Reconciled Cost Of Revenue | - | 9.68 | 11.91 | 12.32 | 15.31 |
| Total Unusual Items | 2.18 | 0 | - | - | - |
| Total Unusual Items Excluding Goodwill | 2.18 | 0 | - | - | - |
| Preferred Stock Dividends | - | 1.34 | 1.34 | 1.31 | 1.27 |
| Special Income Charges | 2.18 | 0 | - | - | - |
| Other Special Charges | -2.18 | - | - | - | - |
| General And Administrative Expense | - | 14.36 | 14.05 | 17.20 | 17.85 |
| Other Gand A | - | 14.36 | 14.05 | 17.20 | 17.85 |
| Rent Expense Supplemental | 0.99 | 0 | - | - | - |
| Total Other Finance Cost | 0.01 | -0.48 | - | - | - |
| Other Operating Expenses | - | - | - | - | -0.49 |
| Selling And Marketing Expense | - | 12.32 | 12.38 | 12.37 | 12.44 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Stereotaxis, Inc.this co. | STXS | $184M | -8.49 | 13.63 | -160.5% | -8.55 |
| Lucid Diagnostics Inc. | LUCD | $195M | - | 17.79 | -645.1% | - |
| Cartesian Therapeutics, Inc. | RNAC | $192M | -1.48 | -1.52 | 103.2% | -0.96 |
| KORU Medical Systems, Inc. | KRMD | $190M | -72.09 | 11.15 | -15.5% | -85.47 |
| Tonix Pharmaceuticals Holding Corp. | TNXP | $189M |
| - |
| - |
| - |
| - |
| - |
| -1.53 |
| 0.77 |
| -50.6% |
| 0.14 |
| MediWound Ltd. | MDWD | $186M | -7.78 | 4.26 | -54.7% | -8.81 |
| Quanterix Corporation | QTRX | $179M | -1.67 | 0.61 | -36.2% | -2.05 |
| Journey Medical Corporation | DERM | $171M | -14.98 | 5.38 | -35.9% | -51.87 |
| Inogen, Inc. | INGN | $171M | -7.51 | 0.89 | -11.8% | -8.86 |
| Peer Median | - | -7.51 | 2.57 | -36.1% | -8.81 | |